MKI67 and breast carcinoma: In 2007, the American Society of Clinical Oncology (ASCO) updated its recommendations for the use of tumor markers in breast cancer and pointed out that immunohistochemically detected proliferation markers including Ki-67 should not be recommended for clinical practice because of an insufficient level of evidence and a lack of standardization of assay reagents, procedures, and scoring [6].